Abstract | BACKGROUND: OBJECTIVES: SEARCH STRATEGY: We updated the previous Cochrane review by searching the Cochrane Schizophrenia Group Register (September 2003). We searched references for further trial citations and, where possible, contacted authors. SELECTION CRITERIA: DATA COLLECTION AND ANALYSIS: Working independently, we selected and critically appraised studies, extracted data and analysed on an intention-to-treat basis. Where possible and appropriate we calculated risk ratios (RR) and their 95% confidence intervals (CI) with the number needed to treat (NNT). For continuous data Weighted Mean Differences (WMD) were calculated. MAIN RESULTS: We identified eight small poorly reported studies for inclusion. For the outcome of 'no clinically important improvement in tardive dyskinesia' GABA agonist drugs were not clearly better than placebo (n = 108, RR 0.83 CI 0.6 to 1.1). Deterioration in mental state was more likely to occur in people receiving GABA medication (n = 95, RR 2.47 CI 1.1 to 5.4), but this effect was influenced by the decision to assign a negative outcome to those who dropped out before the end of the study. A greater proportion of people allocated GABA medication may fail to complete the trial compared with those allocated placebo (20% versus 9%), but this difference was not statistically significant (n = 136, RR 1.99 CI 0.8 to 4.7). There is a suggestion of an increase in ataxia (loss of power of muscular coordination) for both baclofen and sodium valproate (n = 95, RR 3.26 CI 0.4 to 30.2), and in sedation (n = 113, RR 2.12 CI 0.8 to 5.4) compared with placebo, but this was not significant. Withdrawal of tetrahydroisoxazolopyridine ( THIP) may cause seizures. REVIEWERS' CONCLUSIONS:
|
Authors | K Soares, J Rathbone, J Deeks |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Issue 4
Pg. CD000203
(Oct 18 2004)
ISSN: 1469-493X [Electronic] England |
PMID | 15494993
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Chemical References |
- Antipsychotic Agents
- GABA Agonists
|
Topics |
- Antipsychotic Agents
(adverse effects)
- Dyskinesia, Drug-Induced
(drug therapy, etiology)
- GABA Agonists
(therapeutic use)
- Humans
- Randomized Controlled Trials as Topic
|